Spero Therapeutics, Inc. (SPRO) Earnings History
Annual and quarterly earnings data from 2015 to 2024
Loading earnings history...
SPRO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SPRO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | -101.7% | -152.9% | -142.9% |
| 2023 | 50.4% | 20.7% | 22.0% |
| 2022 | 100.0% | -86.9% | -95.5% |
| 2021 | 100.0% | -2865.5% | -2923.6% |
| 2020 | -618.1% | -847.9% | -839.0% |
Download Data
Export SPRO earnings history in CSV or JSON format
Free sign-in required to download data
Spero Therapeutics, Inc. (SPRO) Earnings Overview
As of May 8, 2026, Spero Therapeutics, Inc. (SPRO) reported trailing twelve-month net income of -$44M, reflecting -395.3% year-over-year growth. The company earned $-0.78 per diluted share over the past four quarters, with a net profit margin of -142.9%.
Looking at the long-term picture, SPRO's historical earnings data spans multiple years. The company achieved its highest annual net income of $23M in fiscal 2023.
Spero Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including VNDA (-$240M net income, -102.0% margin), PRAX (-$327M net income), NAOV (-$4M net income, -144.8% margin), SPRO has room to improve margins relative to the peer group. Compare SPRO vs VNDA →
SPRO Earnings vs Peers
Earnings metrics vs comparable public companies
SPRO Historical Earnings Data (2015–2024)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$69M | -400.6% | -$73M | $-1.27 | -142.9% | -152.9% |
| 2023 | $23M | +149.1% | $21M | $0.43 | 22.0% | 20.7% |
| 2022 | -$46M | +48.3% | -$42M | $-1.23 | -95.5% | -86.9% |
| 2021 | -$90M | -14.7% | -$88M | $-2.91 | -2923.6% | -2865.5% |
| 2020 | -$78M | -28.5% | -$79M | $-3.52 | -839.0% | -847.9% |
| 2019 | -$61M | -46.2% | -$63M | $-3.31 | -335.7% | -348.4% |
| 2018 | -$42M | +9.6% | -$43M | $-2.60 | -1050.5% | -1079.3% |
| 2017 | -$46M | -80.8% | -$42M | $-17.82 | -2329.3% | -2108.6% |
| 2016 | -$25M | -151.0% | -$33M | $-3.86 | -7609.3% | -9916.7% |
| 2015 | -$10M | - | -$13M | $-1.54 | - | - |
See SPRO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SPRO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SPRO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSPRO — Frequently Asked Questions
Quick answers to the most common questions about buying SPRO stock.
Is SPRO growing earnings?
SPRO EPS fell to $-0.78, with earnings declining -395.3%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-44M.
What are SPRO's profit margins?
Spero Therapeutics, Inc. net margin is -142.9%, with operating margin at -152.9%. Below-average margins reflect competitive or cost pressures.
How consistent are SPRO's earnings?
SPRO earnings data spans 2015-2024. The declining earnings trend is -395.3% YoY. Historical data enables comparison across business cycles.